Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03656835 · ClinicalTrials.gov registry record · NA
Nanochip Technology in Monitoring Treatment Response and Detecting Relapse in Participants With Diffuse Large B-Cell Lymphoma
A NA study of Diffuse Large B Cell Lymphoma and High Grade B-Cell Lymphoma, sponsored by Ohio State University Comprehensive Cancer Center.
- Active
- Registry status
- NA
- Development phase
- 73
- Enrollment target
- 1
- Study location
NCT03656835 is a NA study of Diffuse Large B Cell Lymphoma and High Grade B-Cell Lymphoma that is active but no longer recruiting, run by Ohio State University Comprehensive Cancer Center. The registered enrollment target is 73 participants, below the 218-participant average among 114 other Diffuse Large B Cell Lymphoma trials with a reported enrollment target (67% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03656835, a NA study of Diffuse Large B Cell Lymphoma and High Grade B-Cell Lymphoma, is active but no longer recruiting, sponsored by Ohio State University Comprehensive Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 73 participants
- Enrollment target
- 1
- Study location
Study Summary
This trial studies how well nanochip technology (immuno-tethered lipoplex nanoparticle \[ILN\] biochip) works in monitoring treatment response and in detecting relapse in participants with diffuse large B-cell lymphoma. Finding genetic markers for diffuse large B-cell lymphoma may help identify participants with this disease and help predict the outcome of treatment. It is not yet known how well ILN biochip-based testing monitors treatment response or detects relapse in participants with diffuse large B-cell lymphoma.
Conditions Studied
Interventions
- PROCEDURE Molecular Nanotechnology
Study Locations (1)
Ohio
- Ohio State University Comprehensive Cancer Center - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 73 participants |
| Start Date | 2018-09-26 |
| Est. Completion | 2026-07-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03656835
The ClinicalTrials.gov registry entry for NCT03656835 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 73 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 218-participant average among 114 other Diffuse Large B Cell Lymphoma trials with a reported enrollment target (67% lower). The listed sponsor is Ohio State University Comprehensive Cancer Center, which has 341 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Diffuse Large B Cell Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which Molecular Nanotechnology is the first listed.
NCT03656835 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.
Frequently Asked Questions
What is clinical trial NCT03656835 about?
NCT03656835 is a clinical study titled "Nanochip Technology in Monitoring Treatment Response and Detecting Relapse in Participants With Diffuse Large B-Cell Lymphoma". This trial studies how well nanochip technology (immuno-tethered lipoplex nanoparticle \[ILN\] biochip) works in monitoring treatment response and in detecting relapse in participants with diffuse large B-cell lymphoma. Finding genetic markers for diffuse large B-cell lymphoma may help identify part...
What is the current status of trial NCT03656835?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 73 participants. The study started on 2018-09-26. Estimated completion is 2026-07-01.
What conditions does trial NCT03656835 study?
This clinical trial studies the following conditions: Diffuse Large B Cell Lymphoma, High Grade B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type.
What interventions are being tested in trial NCT03656835?
The interventions under investigation include: Molecular Nanotechnology (PROCEDURE).
Who is sponsoring clinical trial NCT03656835?
This trial is sponsored by Ohio State University Comprehensive Cancer Center, which has 341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03656835 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diffuse Large B Cell Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
ctDNA-guided Therapy Optimization in Newly Diagnosed DLBCL
RECRUITING · NA
-
Hyperfractionated Dual Equivalent Fractionated Radiation Therapy
RECRUITING · NA
-
Dose-Reduced Consolidation Radiation Therapy in Patients With Diffuse Large B-cell Lymphoma
ACTIVE NOT RECRUITING · NA
-
Cholecalciferol in Improving Survival in Patients With Newly Diagnosed Cancer With Vitamin D Insufficiency
ACTIVE NOT RECRUITING · NA
-
Use of a Patient Preferences Shared Decision-Making Encounter Tool in Clinical Practice for Patients With DLBCL and FL
COMPLETED · NA
-
Adaptive Bridging RT in R/R B-cell Lymphoma (Pre-CAR T)
COMPLETED · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.